Medifast (MED) Net Margin (2010 - 2026)

Medifast has reported Net Margin for 17 years, with the latest figure at 2.79% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin fell 212.0% year-over-year to 2.79%; the trailing twelve-month figure through Mar 2026 stood at 5.78% (down 448.0% YoY), and the FY2025 full-year result was 4.83%, down 518.0% from the prior year.
• Net Margin for Q1 2026 stood at 2.79%, up from 24.08% in the prior quarter.
• The five-year high for Net Margin was 11.45% in Q1 2023, with the low at 24.08% in Q4 2025.
• Historically, Net Margin has averaged 2.59% across 5 years, with a median of 3.16% in 2023.
• The largest YoY upside for Net Margin was 718 bps in 2025 against a maximum downside of 2474 bps in 2025.
• Medifast's Net Margin stood at 7.86% in 2022, then slumped by 60 bps to 3.16% in 2023, then tumbled by 79 bps to 0.65% in 2024, then tumbled by 3779 bps to 24.08% in 2025, then surged by 88 bps to 2.79% in 2026.
• The last three Net Margin figures came in at 2.79% (Q1 2026), 24.08% (Q4 2025), and 2.52% (Q3 2025), per Business Quant data.